PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE.
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_112
Abstract: Introduction: Despite high overall 5‐year survival rates for childhood HL and sALCL, improved options are needed for patients (pts) who do not respond to, or relapse following, initial therapy. This phase 1/ 2 open‐label, dose‐escalation… read more here.
Keywords: salcl pts; pts treated; treatment; brentuximab vedotin ... See more keywords
RESPONSE‐ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.26_2629
Abstract: Introduction: This study regimen is based on theGPOH-HD 2002 study that demonstrated 5-year EFS and OS of 87% and 95% respectively with 6 cycles OEPA/COPDAC and 20-30 Gy IFRT. The subsequent EuroNet-C1 study showed that… read more here.
Keywords: hodgkin lymphoma; response; classical hodgkin; study ... See more keywords
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03662-6
Abstract: This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who… read more here.
Keywords: year; cell transplantation; stem cell; allogeneic stem ... See more keywords
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00768-6
Abstract: SummaryPurpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid… read more here.
Keywords: solid tumors; study; phase open; open label ... See more keywords
Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-018-2743-6
Abstract: We read with interest the article by Corbin et al. on the characterization of treatment-emergent peripheral neuropathy (PN) in patients with mycosis fungoides and Sézary syndrome (MF/SS) receiving brentuximab vedotin (BV), recently published in your… read more here.
Keywords: grade; peripheral neuropathy; treatment; study ... See more keywords
[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Sign Up to like & getrecommendations! Published in 2020 at "Annales de dermatologie et de venereologie"
DOI: 10.1016/j.annder.2019.09.615
Abstract: BACKGROUND Brentuximab-vedotin (BV), an anti-CD30 agent combined with an anti-neoplastic agent, has recently yielded promising results in the treatment of cutaneous T-lymphomas such as Sezary syndrome. Surprisingly, these results are observed regardless of levels of CD30 expression… read more here.
Keywords: brentuximab vedotin; skin lesions; sezary syndrome; ulceration ... See more keywords
Drug rash with eosinophilia and systemic symptoms related to brentuximab vedotin: A report of 2 cases
Sign Up to like & getrecommendations! Published in 2020 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2020.08.020
Abstract: DRESS: drug reaction with eosinophilia and systemic symptoms INTRODUCTION Brentuximab vedotin is a monoclonal antibody targeting CD30 cells, first approved by the Food and Drug Administration for the treatment of CD30 cutaneous T-cell lymphoma in… read more here.
Keywords: report cases; drug; systemic symptoms; eosinophilia systemic ... See more keywords
Adverse reactions related to brentuximab vedotin use: A real-life retrospective study.
Sign Up to like & getrecommendations! Published in 2019 at "Therapie"
DOI: 10.1016/j.therap.2018.07.004
Abstract: Post-marketing data regarding brentuximab vedotin (BV) are sparse. The aim of this study was to assess the frequency and nature of significant adverse drug reactions (ADRs) in patients treated with BV in a real-world setting.… read more here.
Keywords: brentuximab vedotin; retrospective study; study;
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2020.1718103
Abstract: ABSTRACT Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients. Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab… read more here.
Keywords: brentuximab vedotin; vedotin; risk adverse; lymphoma patients ... See more keywords
An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2019.1658522
Abstract: ABSTRACT Introduction: Outcomes of patients with classical Hodgkin lymphoma are excellent, and the intent of frontline therapy for even advanced-stage disease has been curative. This review summarizes the role of brentuximab vedotin in the upfront… read more here.
Keywords: treatment; brentuximab vedotin; stage; hodgkin lymphoma ... See more keywords
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx791
Abstract: Background We previously demonstrated that brentuximab vedotin (BV) used as second-line therapy in patients with Hodgkin lymphoma is a tolerable and effective bridge to autologous hematopoietic cell transplantation (AHCT). Here, we report the post-AHCT outcomes… read more here.
Keywords: escalation; hodgkin lymphoma; line; cell transplantation ... See more keywords